Effect of equilibration time on clinical and neonatal outcomes in human blastocysts vitrification.
blastocyst
clinical and neonatal outcomes
cryoprotectant
equilibration time
vitrification
Journal
Reproductive medicine and biology
ISSN: 1445-5781
Titre abrégé: Reprod Med Biol
Pays: Japan
ID NLM: 101213278
Informations de publication
Date de publication:
Jul 2020
Jul 2020
Historique:
received:
05
01
2020
revised:
29
03
2020
accepted:
16
04
2020
entrez:
21
7
2020
pubmed:
21
7
2020
medline:
21
7
2020
Statut:
epublish
Résumé
Prolonged exposure to equilibration solutions may be detrimental to an embryo's developmental potential, whereas a shorter exposure may affect the penetration of cryoprotectants into blastomeres. The purpose of this study was to evaluate the effects of different equilibration times on the clinical and neonatal outcomes of human blastocyst vitrification. This is a retrospective study based on data collected between November 2008 and November 2015. A total of 192 blastocysts (80 non-expanded and 112 expanded) obtained from 167 patients were analyzed. The blastocysts were divided into two groups according to their equilibration time: 8-11 minutes or 12-15 minutes. The clinical and neonatal outcomes of warmed blastocysts were evaluated. The survival, implantation, and live birth rates of non-expanded blastocysts were not different between the two groups, but they significantly improved for the expanded blastocysts in the 12-15 minutes group compared to the 8-11 minutes group. The results were similar for the neonatal outcomes after vitrified embryo transfer, when partitioned by equilibration time and blastocyst stage at vitrification. For the non-expanded blastocysts, a shortened equilibration time (8-11 minutes) is sufficient for effective vitrification.
Identifiants
pubmed: 32684826
doi: 10.1002/rmb2.12328
pii: RMB212328
pmc: PMC7360958
doi:
Types de publication
Journal Article
Langues
eng
Pagination
270-276Informations de copyright
© 2020 The Authors. Reproductive Medicine and Biology published by John Wiley & Sons Australia, Ltd on behalf of Japan Society for Reproductive Medicine.
Déclaration de conflit d'intérêts
Shingo Mitsuhata, Yoshitaka Fujii, Yuji Endo, Momoko Hayashi and Hiroaki Motoyama declare that they have no conflict of interest.
Références
Hum Reprod. 2002 Mar;17(3):744-51
pubmed: 11870130
Fertil Steril. 2012 Jun;97(6):1338-42
pubmed: 22464083
J Assist Reprod Genet. 2016 Apr;33(4):467-71
pubmed: 26843389
Reprod Med Biol. 2020 Mar 18;19(2):198-205
pubmed: 32273827
Hum Reprod. 2011 Jun;26(6):1270-83
pubmed: 21502182
Reprod Biomed Online. 2015 Jun;30(6):613-21
pubmed: 25892497
Fertil Steril. 2009 Jul;92(1):143-8
pubmed: 18692781
Lancet. 2019 Mar 30;393(10178):1310-1318
pubmed: 30827784
Fertil Steril. 2017 Oct;108(4):659-666.e4
pubmed: 28863936
J Ovarian Res. 2012 Oct 05;5(1):27
pubmed: 23039212
Reprod Biomed Online. 2005 Nov;11(5):608-14
pubmed: 16409712
Fertil Steril. 2010 May 15;93(8):2640-5
pubmed: 19732878
Hum Fertil (Camb). 2016 Jun;19(2):114-9
pubmed: 27218702
Hum Reprod. 2003 Feb;18(2):384-91
pubmed: 12571178
Fertil Steril. 2012 Nov;98(5):1138-46.e1
pubmed: 22862909
Reprod Med Biol. 2019 May 11;18(3):284-289
pubmed: 31312108
Fertil Steril. 2005 Jul;84(1):88-92
pubmed: 16009162